Core One Labs’ Upgrades to OTCQB Venture Market
06 avr. 2022 08h30 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences...
Core One Labs’ Akome Receives Positive Results from Bioassay Studies
02 avr. 2022 08h55 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 02, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities
15 mars 2022 04h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
03 mars 2022 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, March 03, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”), is pleased to announce that...
Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
21 févr. 2022 16h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT
10 févr. 2022 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that,...
Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development
07 août 2021 19h55 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Aug. 07, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion
05 août 2021 01h15 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is a research and development...
Core One’s Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021
30 juil. 2021 03h10 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
Core One Labs’ Akome Seeks to Revolutionize Treatment of Parkinson’s Disease and Submits Application to Protect IP
26 juil. 2021 07h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce that its wholly...